Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI (glycerol phenylbutyrate) Oral Liquid

Source Link:: http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=960851

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

HZNP

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Horizon Pharma has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/958,259, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved medicine RAVICTI® (glycerol phenylbutyrate) Oral Liquid.

http://ir.horizon-ph...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 16, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Patent, Trademark Office, Ravicti, Glycerol Phenylbutyrate, Oral Liquid